CIDARA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.29 USD | +19.90% |
|
-14.91% | -22.61% |
| 12:07pm | North American Morning Briefing : More Tech -2- | DJ |
| 12:06pm | North American Morning Briefing : More Tech Earnings in Focus With GDP Data Adding to the Uncertainty | DJ |
Financials (USD)
| Sales 2024 * | 39.3M | Sales 2025 * | 45.96M | Capitalization | 56.06M |
|---|---|---|---|---|---|
| Net income 2024 * | -35M | Net income 2025 * | -19M | EV / Sales 2024 * | 1.43 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.22 x |
| P/E ratio 2024 * |
-1.93
x | P/E ratio 2025 * |
-16.5
x | Employees | 69 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 1,836.91% |
More Fundamentals
* Assessed data
More news
Latest transcript on Cidara Therapeutics, Inc.
More recommendations
More press releases
More news
| 1 day | +19.90% | ||
| 1 week | -14.91% | ||
| Current month | -33.21% | ||
| 1 month | -20.94% | ||
| 3 months | -10.94% | ||
| 6 months | -27.28% | ||
| Current year | -22.61% |
1 week
10.00
14.80
1 month
10.0024.40
Current year
10.0024.40
1 year
10.0029.60
3 years
8.0047.80
5 years
8.0089.00
10 years
8.00382.60
| Managers | Title | Age | Since |
|---|---|---|---|
Jeffrey Stein
CEO | Chief Executive Officer | 69 | 13-12-31 |
Preetam Shah
DFI | Director of Finance/CFO | 51 | 21-08-31 |
Les Tari
CTO | Chief Tech/Sci/R&D Officer | 57 | 12-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Daniel Burgess
CHM | Chairman | 62 | 14-03-31 |
| Director/Board Member | 69 | 14-03-31 | |
Jeffrey Stein
CEO | Chief Executive Officer | 69 | 13-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 12.29 | +19.90% | 326,436 |
| 24-04-23 | 10.25 | -0.27% | 96,083 |
| 24-04-22 | 10.28 | -24.54% | 192,657 |
| 24-04-19 | 13.62 | -5.68% | 18,245 |
| 24-04-18 | 14.44 | -0.03% | 13,716 |
Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT
More quotes
Cidara Therapeutics, Inc. is a biotechnology company. The Company is focused on the discovery, development and commercialization of therapeutics designed for patients facing serious diseases. The Company's lead product candidate is rezafungin acetate, an intravenous formulation of an echinocandin. Rezafungin is being developed as a once-weekly, high-exposure therapy for the treatment and prevention of serious invasive fungal infections. The Companyâs primary focus is using its Cloudbreak platform to develop a potential new class of drugs called drug-Fc conjugates (DFCs), for the prevention and treatment of serious diseases. This technology couplesâ potent inhibitors to a human antibody fragment to create long-acting DFCs designed to inhibit multiple disease targets. Its advanced DFC program is CD388, a long-acting antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase I and Phase IIa clinical trials.
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
12.29
USD
Average target price
90
USD
Spread / Average Target
+632.30%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -22.61% | 56.06M | |
| -1.51% | 104B | |
| +3.22% | 97.42B | |
| +1.51% | 22.2B | |
| -16.53% | 21.23B | |
| -8.77% | 18.33B | |
| -42.33% | 16.35B | |
| -20.09% | 15.06B | |
| +5.47% | 13.98B | |
| +28.85% | 11.66B |
- Stock Market
- Equities
- CDTX Stock
